GRI Bio (NASDAQ: GRI) — Company Overview, News & Financial Data
GRI Bio is a clinical-stage biotech targeting NKT cells for treatments of inflammatory diseases like pulmonary fibrosis.
GRI GRI Bio
Company profile
GRI Bio
GRI Bio (NASDAQ:GRI) is a clinical-stage biotech taking a new approach to inflammatory diseases. They target NKT cells, immune system regulators, to interrupt disease progression. Their lead program, GRI-0621, is a potential treatment for idiopathic pulmonary fibrosis, a serious lung condition. With a library of over 500 compounds, GRI Bio has the potential for a growing pipeline of treatments.
Snapshot
Public USOwnership
2009Year founded
4Employees
La Jolla, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
United States
Products and/or services of GRI Bio
- Developing therapies: They focus on treatments for inflammatory, fibrotic, and autoimmune diseases.
- NKT cell targeting: Their approach targets Natural Killer T (NKT) cells to regulate the immune system.
- Drug pipeline: They have a pipeline of drug candidates, with GRI-0621 being the most advanced.
- Pre-clinical and clinical trials: Their drugs are currently in pre-clinical and clinical trial phases, not yet available for commercial use.
- Compound library: They have a library of over 500 proprietary compounds which could fuel future drug development.
GRI Bio executive team
- W. Marc HertzCo-Founder, CEO, President & Director
- Vipin Kumar ChaturvediCo-Founder & Chief Scientific Officer
- Leanne M. KellyCFO & Corporate Secretary
- Albert AgroCo-Founder & Chief Medical Officer
Latest news about GRI Bio
Key financials
Reported results for GRI Bio, in USD.
- Market cap
- 3.2M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -14.5
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -12M | -12M | |
| 22.5M | -8.2M | -8.2M | |
| 21.8M | -11.4M | -13M | |
| 0 | -2.2M | -3.2M |